Ardea's Phase III Program For Promising Gout Drug Begins To Take Shape
This article was originally published in The Pink Sheet Daily
Positive efficacy and clean-as-whistle topline results for unpartnered RDEA594 leave some analysts predicting the drug could become a front-runner in the gout field.
You may also be interested in...
Lower dose of oral, uric acid transporter inhibitor shows good efficacy in two of three Phase III trials, but renal safety risk appears to limit lesinurad’s potential market – if it gets approved at all.
The $1.26 billion buyout comes as the pharma is looking to bolt-on acquisitions to help offset recent late-stage pipeline disappointments and sees Ardea’s lesinurad as a potential improvement in gout therapy, an estimated $2 billion global market.
Despite black box warning for anaphylaxis and infusion reactions, label and risk plan are seen as "benign" by analysts.